Details of the Drug

General Information of Drug (ID: DMQ0IZ6)

Drug Name
Lutetium Lu-177 vipivotide tetraxetan
Synonyms 177Lu-labelled PSMA-617
Indication
Disease Entry ICD 11 Status REF
Prostate cancer 2C82.0 Approved [1]
Drug Type
Radiopharmaceutical therapy agent
Cross-matching ID
UNII
G6UF363ECX
DrugBank ID
DB16778
TTD ID
DGQW52

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Glutamate carboxypeptidase II (GCPII) TT9G4N0 FOLH1_HUMAN Not Available [2]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

ICD Disease Classification 02 Neoplasm
Disease Class ICD-11: 2C82 Prostate cancer
The Studied Tissue Prostate
The Studied Disease Prostate cancer [ICD-11:2C82]
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Glutamate carboxypeptidase II (GCPII) DTT FOLH1 1.40E-09 2.08 2.21
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

References

1 FDA Approved Drug Products from FDA Official Website. 2022. Application Number: 215833.
2 [177Lu-PSMA-617 therapy, dosimetry and follow-up in patients with metastatic castration-resistant prostate cancer]. Nuklearmedizin. 2016 Jun 28;55(3):123-8.